Y Intercept Hong Kong Ltd Takes Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Y Intercept Hong Kong Ltd bought a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 13,279 shares of the company’s stock, valued at approximately $338,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Bfsg LLC boosted its stake in shares of BridgeBio Pharma by 175.6% in the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company’s stock valued at $31,000 after purchasing an additional 790 shares in the last quarter. Headlands Technologies LLC bought a new position in BridgeBio Pharma during the 2nd quarter valued at about $48,000. Values First Advisors Inc. acquired a new position in BridgeBio Pharma in the third quarter valued at about $57,000. CWM LLC grew its stake in BridgeBio Pharma by 132.9% during the third quarter. CWM LLC now owns 3,442 shares of the company’s stock worth $88,000 after buying an additional 1,964 shares during the last quarter. Finally, Advisors Asset Management Inc. increased its holdings in shares of BridgeBio Pharma by 56.1% during the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock worth $117,000 after buying an additional 1,645 shares in the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. HC Wainwright restated a “buy” rating and set a $49.00 price target on shares of BridgeBio Pharma in a research report on Monday. Oppenheimer started coverage on BridgeBio Pharma in a research note on Thursday, October 3rd. They issued a “market perform” rating for the company. Scotiabank upped their price target on shares of BridgeBio Pharma from $45.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, November 25th. Leerink Partners decreased their price objective on shares of BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, Bank of America boosted their target price on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $47.69.

Insider Buying and Selling

In other news, CFO Brian C. Stephenson sold 4,156 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $93,135.96. Following the completion of the transaction, the chief financial officer now owns 93,758 shares of the company’s stock, valued at $2,101,116.78. The trade was a 4.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Neil Kumar sold 27,389 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $613,787.49. Following the completion of the transaction, the chief executive officer now directly owns 4,897,443 shares of the company’s stock, valued at approximately $109,751,697.63. The trade was a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 24.66% of the stock is owned by insiders.

BridgeBio Pharma Stock Performance

BBIO opened at $27.82 on Wednesday. The company has a fifty day moving average price of $25.70 and a two-hundred day moving average price of $26.09. The firm has a market capitalization of $5.26 billion, a PE ratio of -11.54 and a beta of 1.08. BridgeBio Pharma, Inc. has a 52 week low of $21.62 and a 52 week high of $44.32.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.